Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PLX | Protalix BioTherapeutics, Inc. | 2026-10-15 14:59:58 | 2.69 | 0.07 | 2.67 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLX | 0001006281 | Protalix BioTherapeutics, Inc. | US74365A3095 | 549300SDVB3GP4XDFM60 | 650643773 | NYSE | 2836 | Biological Products, (No Diagnostic Substances) | 1231 | DE | 2 UNIVERSITY PLAZA | HACKENSACK | NJ | 07601 | UNITED STATES | US | 201-696-9345 | 2 UNIVERSITY PLAZA, HACKENSACK, NJ, 07601 | 2 UNIVERSITY PLAZA, HACKENSACK, NJ, 07601 | ORTHODONTIX INC | Biotechnology | 1993 | Moshe Manor | 266 | http://protalix.com | 113,100,000 | 80,425,981 | 80,571,642 | Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. | 2026-10-16 04:23:08 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 113,100,000 | 31,100,000 | 37.9268 | 80,571,642 | 2,539,057 | 3.2538 |
| 2024 | 82,000,000 | -57,300,000 | -41.1342 | 78,032,585 | 4,980,461 | 6.8177 |
| 2023 | 139,300,000 | 87,100,000 | 166.8582 | 73,052,124 | 7,637,207 | 11.675 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Yaron Naos | Senior Vice President, Chief Operating Officer | 2025 | 232,784 | 90,115 | 77,804 | — | 95,240 | 575,769 |
| Dror Bashan | Chief Executive Officer, President | 2025 | 401,836 | 279,491 | 190,015 | — | 126,575 | 1,166,934 |
| Gilad Mamlok | Chief Financial Officer, Senior Vice President | 2025 | 133,919 | 0 | 0 | — | 41,577 | 405,225 |
| Eyal Rubin | Chief Financial Officer, Senior Vice President | 2025 | 240,576 | 181,208 | 183,393 | — | 195,832 | 832,461 |
| Eyal Rubin | Chief Financial Officer, Senior Vice President | 2024 | 287,363 | 130,399 | 288,669 | — | 97,594 | 859,466 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 226 |
| 2022 | 197 |
| 2021 | 206 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 52,744,000 | 53,399,000 | 65,494,000 |
| Cost Of Revenue | 26,993,000 | 24,319,000 | 22,982,000 |
| Gross Profit | 25,751,000 | 29,080,000 | 42,512,000 |
| Research And Development Expenses | 19,569,000 | 12,970,000 | 17,093,000 |
| General And Administrative Expenses | 11,682,000 | 12,193,000 | 14,959,000 |
| Operating Expenses | 31,251,000 | 25,163,000 | 32,052,000 |
| Operating Income | -5,500,000 | 3,917,000 | 10,460,000 |
| Net Income | -6,604,000 | 2,932,000 | 8,312,000 |
| Earnings Per Share Basic | -0.08 | 0.04 | 0.12 |
| Earnings Per Share Diluted | -0.08 | 0.04 | 0.09 |
| Weighted Average Shares Outstanding Basic | 78,546,234 | 72,530,698 | 67,512,527 |
| Weighted Average Shares Outstanding Diluted | 78,546,234 | 81,057,176 | 82,424,016 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 14,680,000 | 19,760,000 | 23,634,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 8,840,000 | 2,909,000 | 5,272,000 |
| Inventories | 25,729,000 | 21,243,000 | 19,045,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 1,129,000 | 1,096,000 | 1,055,000 |
| Total Assets Current | 66,673,000 | 60,078,000 | 69,932,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 4,879,000 | 4,591,000 | 4,973,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 15,673,000 | 13,339,000 | 14,502,000 |
| Total Assets | 82,346,000 | 73,417,000 | 84,434,000 |
| Accounts Payable | 5,259,000 | 4,533,000 | 19,550,000 |
| Deferred Revenue | — | — | 0 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 9,790,000 | 9,568,000 | 9,009,000 |
| Total Liabilities Current | 26,518,000 | 25,621,000 | 45,530,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 7,598,000 | 4,585,000 | 5,335,000 |
| Total Liabilities | 34,116,000 | 30,206,000 | 50,865,000 |
| Common Stock | 80,000 | 76,000 | 73,000 |
| Retained Earnings | -384,997,000 | -378,393,000 | -381,549,000 |
| Accumulated Other Comprehensive Income | — | — | — |
| Total Shareholders Equity | 48,230,000 | 43,211,000 | 33,569,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,465,000 | 1,304,000 | 1,191,000 |
| Share Based Compensation Expense | 2,297,000 | 3,253,000 | 3,448,000 |
| Other Non Cash Income Expense | 0 | 3,000 | -9,000 |
| Change In Accounts Receivable | 5,890,000 | -2,317,000 | 428,000 |
| Change In Inventories | 4,486,000 | 2,198,000 | 2,241,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 292,000 | 696,000 | 5,295,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -11,993,000 | 8,674,000 | -1,318,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 1,638,000 | 1,282,000 | 1,149,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | 26,000 | -80,000 | 142,000 |
| Cash From Investing Activities | -2,366,000 | 4,221,000 | -16,711,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 6,812,000 | 3,626,000 | 23,954,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 9,326,000 | -16,794,000 | 24,666,000 |
| Change In Cash | -5,080,000 | -3,874,000 | 6,523,000 |
| Cash At End Of Period | 14,680,000 | 19,760,000 | 23,634,000 |
| Income Taxes Paid | 1,183,000 | 385,000 | — |
| Interest Paid | 0 | 1,532,000 | 2,742,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.08 | 0.04 | 0.12 |
| Price To Earnings Ratio | -22.5 | 47 | 14.8333 |
| Earnings Growth Rate | -300 | -66.6667 | -138.7097 |
| Price Earnings To Growth Ratio | 0.075 | -0.705 | -0.1069 |
| Book Value Per Share | 0.614 | 0.5958 | 0.4972 |
| Price To Book Ratio | 2.9314 | 3.1556 | 3.5799 |
| Ebitda | -3,956,000 | 4,621,000 | 9,503,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 1,753,000 | 922,000 | 1,611,000 |
| Free Cash Flow | -13,746,000 | 7,752,000 | -2,929,000 |
| Return On Equity | -0.1369 | 0.0679 | 0.2476 |
| One Year Beta | 0.8787 | 0.6057 | 0.2489 |
| Three Year Beta | 0.658 | 0.5124 | 0.662 |
| Five Year Beta | 0.7086 | 0.6466 | 0.6262 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Forster Eliot | Director | 2026-09-03 | 17,000 | A | 17,000 |
| Forster Eliot | Director | 2026-09-03 | 8,500 | A | 8,500 |
| Ben Zvi Shmuel | Director | 2026-09-03 | 17,000 | A | 17,000 |
| Ben Zvi Shmuel | Director | 2026-09-03 | 8,500 | A | 8,500 |
| Bashan Dror | Director, PRESIDENT AND CEO | 2026-09-03 | 320,000 | A | 320,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Activest Wealth Management | 2026-09-30 | 828 | 300 | 2.76 |
| State of Alaska, Department of Revenue | 2026-09-30 | 60,000 | 21,831 | 2.7484 |
| Fortitude Family Office, LLC | 2026-09-30 | 8,901 | 3,225 | 2.76 |
| Essential Partners LLC | 2026-09-30 | 33 | 12 | 2.75 |
| BAILARD, INC. | 2026-09-30 | 168,636 | 61,100 | 2.76 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VICTORY PORTFOLIOS III | 2026-07-31 | Victory Extended Market Index Fund | USMIX | 8,951 | 21,213.87 | 0.0026 |
| Global X Funds | 2026-07-31 | Global X Russell 2000 ETF | RSSL | 35,366 | 83,817.42 | 0.0056 |
| Voya MUTUAL FUNDS | 2026-07-31 | Class R6 | VVJFX | 5,495 | 90,211.29 | 0.0156 |
| Voya MUTUAL FUNDS | 2026-07-31 | Class W | ISCWX | 5,495 | 90,211.29 | 0.0156 |
| Voya MUTUAL FUNDS | 2026-07-31 | Class I | NAPIX | 5,495 | 90,211.29 | 0.0156 |